ID   MYLK_HUMAN              Reviewed;        1914 AA.
AC   Q15746; B4DUE3; D3DN97; O95796; O95797; O95798; O95799; Q14844; Q16794;
AC   Q17S15; Q3ZCP9; Q5MY99; Q5MYA0; Q6P2N0; Q7Z4J0; Q9C0L5; Q9UBG5; Q9UBY6;
AC   Q9UIT9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 4.
DT   12-OCT-2022, entry version 226.
DE   RecName: Full=Myosin light chain kinase, smooth muscle {ECO:0000305};
DE            Short=MLCK;
DE            Short=smMLCK;
DE            EC=2.7.11.18 {ECO:0000269|PubMed:11113114};
DE   AltName: Full=Kinase-related protein;
DE            Short=KRP;
DE   AltName: Full=Telokin;
DE   Contains:
DE     RecName: Full=Myosin light chain kinase, smooth muscle, deglutamylated form;
GN   Name=MYLK {ECO:0000312|HGNC:HGNC:7590}; Synonyms=MLCK, MLCK1, MYLK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 9), AND TISSUE SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   PubMed=8575746; DOI=10.1006/geno.1995.9965;
RA   Potier M.-C., Chelot E., Pekarsky Y., Gardiner K., Rossier J.,
RA   Turnell W.G.;
RT   "The human myosin light chain kinase (MLCK) from hippocampus: cloning,
RT   sequencing, expression, and localization to 3qcen-q21.";
RL   Genomics 29:562-570(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=9160829; DOI=10.1165/ajrcmb.16.5.9160829;
RA   Garcia J.G.N., Lazar V.L., Gilbert-Mcclain L.I., Gallagher P.J.,
RA   Verin A.D.;
RT   "Myosin light chain kinase in endothelium: molecular cloning and
RT   regulation.";
RL   Am. J. Respir. Cell Mol. Biol. 16:489-494(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3A AND 3B), AND NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1281-1914 (ISOFORM 4).
RC   TISSUE=Umbilical vein;
RX   PubMed=10198165; DOI=10.1006/geno.1999.5774;
RA   Lazar V.L., Garcia J.G.N.;
RT   "A single human myosin light chain kinase gene (MLCK; MYLK).";
RL   Genomics 57:256-267(1999).
RN   [4]
RP   SEQUENCE REVISION (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF 457-476 AND
RP   968-985, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   PHOSPHORYLATION AT TYR-464 AND TYR-471, CALMODULIN-BINDING, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11113114; DOI=10.1074/jbc.m005270200;
RA   Birukov K.G., Csortos C., Marzilli L., Dudek S., Ma S.-F., Bresnick A.R.,
RA   Verin A.D., Cotter R.J., Garcia J.G.N.;
RT   "Differential regulation of alternatively spliced endothelial cell myosin
RT   light chain kinase isoforms by p60(Src).";
RL   J. Biol. Chem. 276:8567-8573(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), NUCLEOTIDE SEQUENCE [GENOMIC DNA /
RP   MRNA] (ISOFORM 8), NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1614-1914 (ISOFORM
RP   9/DEL-1790), AND TISSUE SPECIFICITY.
RC   TISSUE=Lung, and Placenta;
RX   PubMed=10536370;
RX   DOI=10.1002/(sici)1097-4644(19991201)75:3<481::aid-jcb12>3.0.co;2-5;
RA   Watterson D.M., Schavocky J.P., Guo L., Weiss C., Chlenski A.,
RA   Shrinsky V.P., Van Eldik L.J., Haiech J.;
RT   "Analysis of the kinase-related protein gene found at human chromosome 3q21
RT   in a multi-gene cluster: organization, expression, alternative splicing and
RT   polymorphic marker.";
RL   J. Cell. Biochem. 75:481-491(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Intestinal epithelium;
RX   PubMed=15507455; DOI=10.1074/jbc.m408822200;
RA   Clayburgh D.R., Rosen S., Witkowski E.D., Wang F., Blair S., Dudek S.,
RA   Garcia J.G., Alverdy J.C., Turner J.R.;
RT   "A differentiation-dependent splice variant of myosin light chain kinase,
RT   MLCK1, regulates epithelial tight junction permeability.";
RL   J. Biol. Chem. 279:55506-55513(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL CYCLE, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15020676; DOI=10.1242/jcs.00993;
RA   Dulyaninova N.G., Patskovsky Y.V., Bresnick A.R.;
RT   "The N-terminus of the long MLCK induces a disruption in normal spindle
RT   morphology and metaphase arrest.";
RL   J. Cell Sci. 117:1481-1493(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RC   TISSUE=Cervix carcinoma;
RA   Kikuchi A., Murata-Hori M., Hosoya H.;
RT   "HeLa myosin light chain kinase.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6; 7 AND 8).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 8).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1456-1914 (ISOFORM 9/DEL-1790).
RC   TISSUE=Placenta;
RA   Watterson D.M.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   INTERACTION WITH CTTN, AND PHOSPHORYLATION AT TYR-464 AND TYR-471 BY SRC.
RX   PubMed=12408982; DOI=10.1016/s0006-291x(02)02492-0;
RA   Dudek S.M., Birukov K.G., Zhan X., Garcia J.G.N.;
RT   "Novel interaction of cortactin with endothelial cell myosin light chain
RT   kinase.";
RL   Biochem. Biophys. Res. Commun. 298:511-519(2002).
RN   [15]
RP   FUNCTION IN HYPOTONICITY RESPONSE, AND ACTIVITY REGULATION.
RX   PubMed=11976941; DOI=10.1007/s00424-002-0811-3;
RA   Shen M.-R., Furla P., Chou C.-Y., Ellory J.C.;
RT   "Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry and
RT   Cl- channel activity in human cervical cancer cells.";
RL   Pflugers Arch. 444:276-285(2002).
RN   [16]
RP   ACTIVITY REGULATION BY CALCIUM.
RX   PubMed=14741352; DOI=10.1016/s0014-5793(03)01456-x;
RA   Geguchadze R., Zhi G., Lau K.S., Isotani E., Persechini A., Kamm K.E.,
RA   Stull J.T.;
RT   "Quantitative measurements of Ca(2+)/calmodulin binding and activation of
RT   myosin light chain kinase in cells.";
RL   FEBS Lett. 557:121-124(2004).
RN   [17]
RP   FUNCTION IN WOUND HEALING.
RX   PubMed=15825080; DOI=10.1053/j.gastro.2005.01.004;
RA   Russo J.M., Florian P., Shen L., Graham W.V., Tretiakova M.S., Gitter A.H.,
RA   Mrsny R.J., Turner J.R.;
RT   "Distinct temporal-spatial roles for rho kinase and myosin light chain
RT   kinase in epithelial purse-string wound closure.";
RL   Gastroenterology 128:987-1001(2005).
RN   [18]
RP   INDUCTION BY TNF, TISSUE SPECIFICITY, AND ALTERNATIVE PROMOTER USAGE
RP   (ISOFORMS 1/2/3A/3B/4/DEL-1790).
RX   PubMed=16835238; DOI=10.1074/jbc.m602164200;
RA   Graham W.V., Wang F., Clayburgh D.R., Cheng J.X., Yoon B., Wang Y., Lin A.,
RA   Turner J.R.;
RT   "Tumor necrosis factor-induced long myosin light chain kinase transcription
RT   is regulated by differentiation-dependent signaling events.
RT   Characterization of the human long myosin light chain kinase promoter.";
RL   J. Biol. Chem. 281:26205-26215(2006).
RN   [19]
RP   FUNCTION IN EPITHELIAL CELL SURVIVAL, AND ACTIVITY REGULATION.
RX   PubMed=16723733; DOI=10.1242/jcs.02926;
RA   Connell L.E., Helfman D.M.;
RT   "Myosin light chain kinase plays a role in the regulation of epithelial
RT   cell survival.";
RL   J. Cell Sci. 119:2269-2281(2006).
RN   [20]
RP   FUNCTION IN TRPC5 REGULATION, ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=16284075; DOI=10.1113/jphysiol.2005.097998;
RA   Shimizu S., Yoshida T., Wakamori M., Ishii M., Okada T., Takahashi M.,
RA   Seto M., Sakurada K., Kiuchi Y., Mori Y.;
RT   "Ca2+-calmodulin-dependent myosin light chain kinase is essential for
RT   activation of TRPC5 channels expressed in HEK293 cells.";
RL   J. Physiol. (Lond.) 570:219-235(2006).
RN   [21]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=18710790; DOI=10.1016/j.canlet.2008.05.028;
RA   Zhou X., Liu Y., You J., Zhang H., Zhang X., Ye L.;
RT   "Myosin light-chain kinase contributes to the proliferation and migration
RT   of breast cancer cells through cross-talk with activated ERK1/2.";
RL   Cancer Lett. 270:312-327(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [23]
RP   FUNCTION AS PTK2B/PYK2 KINASE, AND INTERACTION WITH PTK2B/PYK2.
RX   PubMed=18587400; DOI=10.1038/ni.1628;
RA   Xu J., Gao X.-P., Ramchandran R., Zhao Y.-Y., Vogel S.M., Malik A.B.;
RT   "Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in
RT   sepsis-induced lung inflammation by activating beta2 integrins.";
RL   Nat. Immunol. 9:880-886(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1438, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   INDUCTION BY ANDROGENS.
RX   PubMed=19429448; DOI=10.1016/j.jsbmb.2009.02.002;
RA   Leveille N., Fournier A., Labrie C.;
RT   "Androgens down-regulate myosin light chain kinase in human prostate cancer
RT   cells.";
RL   J. Steroid Biochem. Mol. Biol. 114:174-179(2009).
RN   [27]
RP   FUNCTION IN TUMOR CELL MIGRATION, ACETYLATION AT LYS-608 BY NAA10/ARD1,
RP   INTERACTION WITH NAA10/ARD1, AND MUTAGENESIS OF LYS-608.
RX   PubMed=19826488; DOI=10.1371/journal.pone.0007451;
RA   Shin D.H., Chun Y.-S., Lee K.-H., Shin H.-W., Park J.-W.;
RT   "Arrest defective-1 controls tumor cell behavior by acetylating myosin
RT   light chain kinase.";
RL   PLoS ONE 4:E7451-E7451(2009).
RN   [28]
RP   FUNCTION IN BREAST CANCER.
RX   PubMed=20453870; DOI=10.1038/aps.2010.56;
RA   Cui W.-J., Liu Y., Zhou X.-L., Wang F.-Z., Zhang X.-D., Ye L.-H.;
RT   "Myosin light chain kinase is responsible for high proliferative ability of
RT   breast cancer cells via anti-apoptosis involving p38 pathway.";
RL   Acta Pharmacol. Sin. 31:725-732(2010).
RN   [29]
RP   FUNCTION IN OPTIC NERVE HEAD ASTROCYTE MIGRATION.
RX   PubMed=20375339; DOI=10.1167/iovs.10-5177;
RA   Miao H., Crabb A.W., Hernandez M.R., Lukas T.J.;
RT   "Modulation of factors affecting optic nerve head astrocyte migration.";
RL   Invest. Ophthalmol. Vis. Sci. 51:4096-4103(2010).
RN   [30]
RP   TISSUE SPECIFICITY, INTERACTION WITH CTTN, AND SUBCELLULAR LOCATION.
RX   PubMed=20053363; DOI=10.1016/j.mvr.2009.12.010;
RA   Brown M., Adyshev D., Bindokas V., Moitra J., Garcia J.G.N., Dudek S.M.;
RT   "Quantitative distribution and colocalization of non-muscle myosin light
RT   chain kinase isoforms and cortactin in human lung endothelium.";
RL   Microvasc. Res. 80:75-88(2010).
RN   [31]
RP   PHOSPHORYLATION AT TYR-231; TYR-464; TYR-556; TYR-611; TYR-792; TYR-846;
RP   TYR-1449; TYR-1575 AND TYR-1635 BY ABL1, AND INTERACTION WITH CTTN AND
RP   ABL1.
RX   PubMed=20861316; DOI=10.1091/mbc.e09-10-0876;
RA   Dudek S.M., Chiang E.T., Camp S.M., Guo Y., Zhao J., Brown M.E.,
RA   Singleton P.A., Wang L., Desai A., Arce F.T., Lal R., Van Eyk J.E.,
RA   Imam S.Z., Garcia J.G.N.;
RT   "Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to
RT   regulate endothelial barrier function.";
RL   Mol. Biol. Cell 21:4042-4056(2010).
RN   [32]
RP   FUNCTION IN MEMBRANE BLEBBING.
RX   PubMed=20181817; DOI=10.1124/mol.110.063859;
RA   Godin C.M., Ferguson S.S.G.;
RT   "The angiotensin II type 1 receptor induces membrane blebbing by coupling
RT   to Rho A, Rho kinase, and myosin light chain kinase.";
RL   Mol. Pharmacol. 77:903-911(2010).
RN   [33]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=20139351; DOI=10.1165/rcmb.2009-0197oc;
RA   Mirzapoiazova T., Moitra J., Moreno-Vinasco L., Sammani S., Turner J.R.,
RA   Chiang E.T., Evenoski C., Wang T., Singleton P.A., Huang Y., Lussier Y.A.,
RA   Watterson D.M., Dudek S.M., Garcia J.G.N.;
RT   "Non-muscle myosin light chain kinase isoform is a viable molecular target
RT   in acute inflammatory lung injury.";
RL   Am. J. Respir. Cell Mol. Biol. 44:40-52(2011).
RN   [34]
RP   ACTIVITY REGULATION.
RX   PubMed=21918590; DOI=10.1021/om200366r;
RA   Blanck S., Cruchter T., Vultur A., Riedel R., Harms K., Herlyn M.,
RA   Meggers E.;
RT   "Organometallic pyridylnaphthalimide complexes as protein kinase
RT   inhibitors.";
RL   Organometallics 30:4598-4606(2011).
RN   [35]
RP   REVIEW ON ASTHMA, AND INDUCTION BY ASTHMA.
RX   PubMed=19011151; DOI=10.1164/rccm.200609-1367oc;
RA   Leguillette R., Laviolette M., Bergeron C., Zitouni N., Kogut P.,
RA   Solway J., Kachmar L., Hamid Q., Lauzon A.-M.;
RT   "Myosin, transgelin, and myosin light chain kinase: expression and function
RT   in asthma.";
RL   Am. J. Respir. Crit. Care Med. 179:194-204(2009).
RN   [36]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORMS 5/9).
RX   PubMed=22015949; DOI=10.1007/s00109-011-0820-9;
RA   Han Y.J., Ma S.F., Wade M.S., Flores C., Garcia J.G.;
RT   "An intronic MYLK variant associated with inflammatory lung disease
RT   regulates promoter activity of the smooth muscle myosin light chain kinase
RT   isoform.";
RL   J. Mol. Med. 90:299-308(2012).
RN   [37]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2 (ISOFORMS 6 AND 8), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 6), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 8), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-305; SER-1438; SER-1772;
RP   SER-1776 AND SER-1779, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   STRUCTURE BY NMR OF 1238-1338.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the eighth Ig-like domain of human myosin light
RT   chain kinase.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [40]
RP   STRUCTURE BY NMR OF 1742-1760 IN COMPLEX WITH CALMODULIN.
RX   PubMed=18462678; DOI=10.1016/j.str.2008.02.017;
RA   Gsponer J., Christodoulou J., Cavalli A., Bui J.M., Richter B.,
RA   Dobson C.M., Vendruscolo M.;
RT   "A coupled equilibrium shift mechanism in calmodulin-mediated signal
RT   transduction.";
RL   Structure 16:736-746(2008).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] ALA-261; ALA-276; HIS-378; VAL-405;
RP   SER-443; GLY-607; ALA-652; CYS-656; MET-692; THR-701; MET-709; VAL-1527 AND
RP   LEU-1588.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS AAT7 MET-1213; THR-1754 AND PRO-1759, VARIANTS VAL-128; HIS-133;
RP   ARG-160; CYS-656; ALA-1085 AND LYS-1399, AND CHARACTERIZATION OF VARIANTS
RP   AAT7 THR-1754 AND PRO-1759.
RX   PubMed=21055718; DOI=10.1016/j.ajhg.2010.10.006;
RA   Wang L., Guo D.C., Cao J., Gong L., Kamm K.E., Regalado E., Li L.,
RA   Shete S., He W.Q., Zhu M.S., Offermanns S., Gilchrist D., Elefteriades J.,
RA   Stull J.T., Milewicz D.M.;
RT   "Mutations in myosin light chain kinase cause familial aortic
RT   dissections.";
RL   Am. J. Hum. Genet. 87:701-707(2010).
RN   [43]
RP   VARIANTS AAT7 1458-GLN--GLU-1914 DEL AND 1487-ARG--GLU-1914 DEL.
RX   PubMed=28401540; DOI=10.1111/cge.13000;
RA   Luyckx I., Proost D., Hendriks J.M.H., Saenen J., Van Craenenbroeck E.M.,
RA   Vermeulen T., Peeters N., Wuyts W., Rodrigus I., Verstraeten A.,
RA   Van Laer L., Loeys B.L.;
RT   "Two novel MYLK nonsense mutations causing thoracic aortic
RT   aneurysms/dissections in patients without apparent family history.";
RL   Clin. Genet. 92:444-446(2017).
RN   [44]
RP   ERRATUM NOTICE OF PUBMED:28401540.
RX   PubMed=29537095; DOI=10.1111/cge.13213;
RA   Luyckx I., Proost D., Hendriks J.M.H., Saenen J., Van Craenenbroeck E.M.,
RA   Vermeulen T., Peeters N., Wuyts W., Rodrigus I., Verstraeten A.,
RA   Van Laer L., Loeys B.L.;
RL   Clin. Genet. 93:938-938(2018).
RN   [45]
RP   VARIANT AAT7 SER-1491, CHARACTERIZATION OF VARIANT AAT7 SER-1491, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=29544503; DOI=10.1186/s13023-018-0769-7;
RA   Shalata A., Mahroom M., Milewicz D.M., Limin G., Kassum F., Badarna K.,
RA   Tarabeih N., Assy N., Fell R., Cohen H., Nashashibi M., Livoff A., Azab M.,
RA   Habib G., Geiger D., Weissbrod O., Nseir W.;
RT   "Fatal thoracic aortic aneurysm and dissection in a large family with a
RT   novel MYLK gene mutation: delineation of the clinical phenotype.";
RL   Orphanet J. Rare Dis. 13:41-41(2018).
RN   [46]
RP   INVOLVEMENT IN MMIHS.
RX   PubMed=28602422; DOI=10.1016/j.ajhg.2017.05.011;
RA   Halim D., Brosens E., Muller F., Wangler M.F., Beaudet A.L., Lupski J.R.,
RA   Akdemir Z.H.C., Doukas M., Stoop H.J., de Graaf B.M., Brouwer R.W.W.,
RA   van Ijcken W.F.J., Oury J.F., Rosenblatt J., Burns A.J., Tibboel D.,
RA   Hofstra R.M.W., Alves M.M.;
RT   "Loss-of-Function Variants in MYLK Cause Recessive Megacystis Microcolon
RT   Intestinal Hypoperistalsis Syndrome.";
RL   Am. J. Hum. Genet. 101:123-129(2017).
CC   -!- FUNCTION: Calcium/calmodulin-dependent myosin light chain kinase
CC       implicated in smooth muscle contraction via phosphorylation of myosin
CC       light chains (MLC). Also regulates actin-myosin interaction through a
CC       non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains.
CC       Involved in the inflammatory response (e.g. apoptosis, vascular
CC       permeability, leukocyte diapedesis), cell motility and morphology,
CC       airway hyperreactivity and other activities relevant to asthma.
CC       Required for tonic airway smooth muscle contraction that is necessary
CC       for physiological and asthmatic airway resistance. Necessary for
CC       gastrointestinal motility. Implicated in the regulation of endothelial
CC       as well as vascular permeability, probably via the regulation of
CC       cytoskeletal rearrangements. In the nervous system it has been shown to
CC       control the growth initiation of astrocytic processes in culture and to
CC       participate in transmitter release at synapses formed between cultured
CC       sympathetic ganglion cells. Critical participant in signaling sequences
CC       that result in fibroblast apoptosis. Plays a role in the regulation of
CC       epithelial cell survival. Required for epithelial wound healing,
CC       especially during actomyosin ring contraction during purse-string wound
CC       closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5
CC       channel activity in a calcium-dependent signaling, by inducing its
CC       subcellular localization at the plasma membrane. Promotes cell
CC       migration (including tumor cells) and tumor metastasis. PTK2B/PYK2
CC       activation by phosphorylation mediates ITGB2 activation and is thus
CC       essential to trigger neutrophil transmigration during acute lung injury
CC       (ALI). May regulate optic nerve head astrocyte migration. Probably
CC       involved in mitotic cytoskeletal regulation. Regulates tight junction
CC       probably by modulating ZO-1 exchange in the perijunctional actomyosin
CC       ring. Mediates burn-induced microvascular barrier injury; triggers
CC       endothelial contraction in the development of microvascular
CC       hyperpermeability by phosphorylating MLC. Essential for intestinal
CC       barrier dysfunction. Mediates Giardia spp.-mediated reduced epithelial
CC       barrier function during giardiasis intestinal infection via
CC       reorganization of cytoskeletal F-actin and tight junctional ZO-1.
CC       Necessary for hypotonicity-induced Ca(2+) entry and subsequent
CC       activation of volume-sensitive organic osmolyte/anion channels (VSOAC)
CC       in cervical cancer cells. Responsible for high proliferative ability of
CC       breast cancer cells through anti-apoptosis.
CC       {ECO:0000269|PubMed:11113114, ECO:0000269|PubMed:11976941,
CC       ECO:0000269|PubMed:15020676, ECO:0000269|PubMed:15825080,
CC       ECO:0000269|PubMed:16284075, ECO:0000269|PubMed:16723733,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:18710790,
CC       ECO:0000269|PubMed:19826488, ECO:0000269|PubMed:20139351,
CC       ECO:0000269|PubMed:20181817, ECO:0000269|PubMed:20375339,
CC       ECO:0000269|PubMed:20453870}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[myosin light chain] = ADP + H(+) + O-phospho-L-
CC         seryl-[myosin light chain]; Xref=Rhea:RHEA:22004, Rhea:RHEA-
CC         COMP:13684, Rhea:RHEA-COMP:13685, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.18;
CC         Evidence={ECO:0000269|PubMed:11113114};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:22005;
CC         Evidence={ECO:0000305|PubMed:11113114};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[myosin light chain] = ADP + H(+) + O-
CC         phospho-L-threonyl-[myosin light chain]; Xref=Rhea:RHEA:53900,
CC         Rhea:RHEA-COMP:13686, Rhea:RHEA-COMP:13687, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.18;
CC         Evidence={ECO:0000269|PubMed:11113114};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53901;
CC         Evidence={ECO:0000305|PubMed:11113114};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- ACTIVITY REGULATION: Isoform 1 is activated by phosphorylation on Tyr-
CC       464 and Tyr-471. Isoforms which lack these tyrosine residues are not
CC       regulated in this way. All catalytically active isoforms require
CC       binding to calcium and calmodulin for activation. Repressed by
CC       organometallic pyridylnaphthalimide complexes, wortmannin, ML-7 (a
CC       synthetic naphthalenesulphonyl derivative that inhibits the binding of
CC       ATP to MLCK) and ML-9. {ECO:0000269|PubMed:11113114,
CC       ECO:0000269|PubMed:11976941, ECO:0000269|PubMed:14741352,
CC       ECO:0000269|PubMed:16284075, ECO:0000269|PubMed:16723733,
CC       ECO:0000269|PubMed:21918590}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.5 uM for MLC (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         KM=7.2 uM for MLC (isoform 2 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         KM=9.3 uM for MLC {ECO:0000269|PubMed:29544503};
CC         Vmax=11.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC         Vmax=10.9 umol/min/mg enzyme (isoform 1 at 22 degrees Celsius)
CC         {ECO:0000269|PubMed:11113114};
CC   -!- SUBUNIT: All isoforms including Telokin bind calmodulin. Interacts with
CC       SVIL (By similarity). Interacts with CTTN; this interaction is reduced
CC       during thrombin-induced endothelial cell (EC) contraction but is
CC       promoted by the barrier-protective agonist sphingosine 1-phosphate
CC       (S1P) within lamellipodia. A complex made of ABL1, CTTN and MYLK
CC       regulates cortical actin-based cytoskeletal rearrangement critical to
CC       sphingosine 1-phosphate (S1P)-mediated endothelial cell (EC) barrier
CC       enhancement. Binds to NAA10/ARD1 and PTK2B/PYK2. {ECO:0000250,
CC       ECO:0000269|PubMed:12408982, ECO:0000269|PubMed:18462678,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:19826488,
CC       ECO:0000269|PubMed:20053363, ECO:0000269|PubMed:20861316}.
CC   -!- INTERACTION:
CC       Q15746; Q9HD26: GOPC; NbExp=3; IntAct=EBI-968482, EBI-349832;
CC       Q15746; P16333: NCK1; NbExp=2; IntAct=EBI-968482, EBI-389883;
CC       Q15746-7; Q92624: APPBP2; NbExp=3; IntAct=EBI-12189939, EBI-743771;
CC       Q15746-7; Q9HD26-2: GOPC; NbExp=5; IntAct=EBI-12189939, EBI-11102276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20053363}. Cell
CC       projection, lamellipodium {ECO:0000269|PubMed:20053363}. Cleavage
CC       furrow {ECO:0000269|PubMed:15020676}. Cytoplasm, cytoskeleton, stress
CC       fiber {ECO:0000269|PubMed:15020676}. Note=Localized to stress fibers
CC       during interphase and to the cleavage furrow during mitosis.
CC       {ECO:0000269|PubMed:15020676}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=11;
CC       Name=1; Synonyms=Non-muscle isozyme;
CC         IsoId=Q15746-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15746-2; Sequence=VSP_004791;
CC       Name=3A;
CC         IsoId=Q15746-3; Sequence=VSP_004794;
CC       Name=3B;
CC         IsoId=Q15746-4; Sequence=VSP_004791, VSP_004794;
CC       Name=4;
CC         IsoId=Q15746-5; Sequence=VSP_004793;
CC       Name=Del-1790;
CC         IsoId=Q15746-6; Sequence=VSP_004795;
CC       Name=5; Synonyms=Smooth-muscle isozyme;
CC         IsoId=Q15746-7; Sequence=VSP_018845;
CC       Name=6; Synonyms=Telokin;
CC         IsoId=Q15746-8; Sequence=VSP_018846;
CC       Name=7;
CC         IsoId=Q15746-9; Sequence=VSP_053791;
CC       Name=8;
CC         IsoId=Q15746-10; Sequence=VSP_018846, VSP_004795;
CC       Name=9;
CC         IsoId=Q15746-11; Sequence=VSP_018845, VSP_004795;
CC   -!- TISSUE SPECIFICITY: Smooth muscle and non-muscle isozymes are expressed
CC       in a wide variety of adult and fetal tissues and in cultured
CC       endothelium with qualitative expression appearing to be neither
CC       tissue- nor development-specific. Non-muscle isoform 2 is the dominant
CC       splice variant expressed in various tissues. Telokin has been found in
CC       a wide variety of adult and fetal tissues. Accumulates in well
CC       differentiated enterocytes of the intestinal epithelium in response to
CC       tumor necrosis factor (TNF). {ECO:0000269|PubMed:10536370,
CC       ECO:0000269|PubMed:16835238, ECO:0000269|PubMed:20053363,
CC       ECO:0000269|PubMed:8575746}.
CC   -!- INDUCTION: Accumulates in individuals with asthma (at protein levels).
CC       Induced by tumor necrosis factor (TNF). Repressed by androgens (e.g.
CC       R1881). {ECO:0000269|PubMed:16835238, ECO:0000269|PubMed:19011151,
CC       ECO:0000269|PubMed:19429448}.
CC   -!- PTM: Can probably be down-regulated by phosphorylation. Tyrosine
CC       phosphorylation by ABL1 increases kinase activity, reverses MLCK-
CC       mediated inhibition of Arp2/3-mediated actin polymerization, and
CC       enhances CTTN-binding. Phosphorylation by SRC at Tyr-464 and Tyr-471
CC       promotes CTTN binding. {ECO:0000269|PubMed:11113114,
CC       ECO:0000269|PubMed:12408982, ECO:0000269|PubMed:20861316}.
CC   -!- PTM: The C-terminus is deglutamylated by AGTPBP1/CCP1, AGBL1/CCP4 and
CC       AGBL4/CCP6, leading to the formation of Myosin light chain kinase,
CC       smooth muscle, deglutamylated form. The consequences of C-terminal
CC       deglutamylation are unknown (By similarity). {ECO:0000250}.
CC   -!- PTM: Acetylated at Lys-608 by NAA10/ARD1 via a calcium-dependent
CC       signaling; this acetylation represses kinase activity and reduces tumor
CC       cell migration. {ECO:0000269|PubMed:19826488}.
CC   -!- DISEASE: Aortic aneurysm, familial thoracic 7 (AAT7) [MIM:613780]: A
CC       disease characterized by permanent dilation of the thoracic aorta
CC       usually due to degenerative changes in the aortic wall. It is primarily
CC       associated with a characteristic histologic appearance known as 'medial
CC       necrosis' or 'Erdheim cystic medial necrosis' in which there is
CC       degeneration and fragmentation of elastic fibers, loss of smooth muscle
CC       cells, and an accumulation of basophilic ground substance.
CC       {ECO:0000269|PubMed:21055718, ECO:0000269|PubMed:28401540,
CC       ECO:0000269|PubMed:29544503}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Megacystis-microcolon-intestinal hypoperistalsis syndrome
CC       (MMIHS) [MIM:249210]: A form of megacystis-microcolon-intestinal
CC       hypoperistalsis syndrome, a congenital visceral myopathy primarily
CC       affecting females, and characterized by loss of smooth muscle
CC       contraction in the bladder and intestine. Affected individuals present
CC       at birth with functional obstruction of intestine, microcolon, dilation
CC       of bladder, and secondary hydronephrosis. The majority of cases have a
CC       fatal outcome due to malnutrition and sepsis, followed by multiorgan
CC       failure. MMIHS inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:28602422}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In asthmatic patients, overexpression promotes actin
CC       filament propulsion, thus contributing to airway hyperresponsiveness.
CC       Some MYLK variants may contribute to acute lung injury (ALI)
CC       susceptibility. Potential therapeutic target in the treatment of burn
CC       edema. {ECO:0000305|PubMed:19011151}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Transcribed from an alternative promoter
CC       resulting in the usage of Met-923 as initiator codon.
CC       {ECO:0000269|PubMed:22015949}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Transcribed from an alternative promoter
CC       resulting in the usage of Met-1761 as initiator codon. Has no catalytic
CC       activity. Initiator Met is removed. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Transcribed from an alternative promoter
CC       resulting in the usage of Met-1761 as initiator codon. Initiator Met is
CC       removed. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Transcribed from an alternative promoter
CC       resulting in the usage of Met-923 as initiator codon.
CC       {ECO:0000269|PubMed:22015949}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD15922.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAD15923.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAD15924.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Myosin light-chain kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Myosin_light-chain_kinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MYLKID43364ch3q21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X85337; CAA59685.1; -; mRNA.
DR   EMBL; U48959; AAC18423.2; -; mRNA.
DR   EMBL; AF069601; AAD15921.2; -; mRNA.
DR   EMBL; AF069602; AAD15922.1; ALT_FRAME; mRNA.
DR   EMBL; AF069603; AAD15923.1; ALT_FRAME; mRNA.
DR   EMBL; AF069604; AAD15924.1; ALT_FRAME; mRNA.
DR   EMBL; AF096771; AAD51380.1; -; Genomic_DNA.
DR   EMBL; AF096766; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096767; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096768; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096769; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51380.1; JOINED; Genomic_DNA.
DR   EMBL; AF096771; AAD51381.1; -; Genomic_DNA.
DR   EMBL; AF096769; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096770; AAD51381.1; JOINED; Genomic_DNA.
DR   EMBL; AF096773; AAD54017.1; -; mRNA.
DR   EMBL; AF096774; AAD54018.1; -; mRNA.
DR   EMBL; AF096775; AAD54019.1; -; mRNA.
DR   EMBL; AY424269; AAR29061.1; -; mRNA.
DR   EMBL; AY424270; AAR29062.1; -; mRNA.
DR   EMBL; AY339601; AAQ02673.1; -; mRNA.
DR   EMBL; AB037663; BAB21504.1; -; mRNA.
DR   EMBL; AK300610; BAG62305.1; -; mRNA.
DR   EMBL; AK314412; BAG37033.1; -; mRNA.
DR   EMBL; AK314443; BAG37052.1; -; mRNA.
DR   EMBL; AC020634; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC023165; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79438.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79439.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79440.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79441.1; -; Genomic_DNA.
DR   EMBL; BC100761; AAI00762.2; -; mRNA.
DR   EMBL; BC100762; AAI00763.2; -; mRNA.
DR   EMBL; BC100763; AAI00764.2; -; mRNA.
DR   EMBL; BC064420; AAH64420.2; -; mRNA.
DR   EMBL; X90870; CAA62378.1; -; mRNA.
DR   CCDS; CCDS3023.1; -. [Q15746-3]
DR   CCDS; CCDS43141.1; -. [Q15746-2]
DR   CCDS; CCDS46896.1; -. [Q15746-1]
DR   CCDS; CCDS46897.1; -. [Q15746-8]
DR   CCDS; CCDS58849.1; -. [Q15746-10]
DR   RefSeq; NP_001308238.1; NM_001321309.1.
DR   RefSeq; NP_444253.3; NM_053025.3. [Q15746-1]
DR   RefSeq; NP_444254.3; NM_053026.3. [Q15746-2]
DR   RefSeq; NP_444255.3; NM_053027.3. [Q15746-3]
DR   RefSeq; NP_444256.3; NM_053028.3. [Q15746-4]
DR   RefSeq; NP_444259.1; NM_053031.3. [Q15746-10]
DR   RefSeq; NP_444260.1; NM_053032.3. [Q15746-8]
DR   RefSeq; XP_011511162.1; XM_011512860.2.
DR   RefSeq; XP_016861958.1; XM_017006469.1. [Q15746-11]
DR   RefSeq; XP_016861960.1; XM_017006471.1. [Q15746-9]
DR   RefSeq; XP_016861961.1; XM_017006472.1. [Q15746-8]
DR   RefSeq; XP_016861962.1; XM_017006473.1. [Q15746-10]
DR   PDB; 2CQV; NMR; -; A=1238-1338.
DR   PDB; 2K0F; NMR; -; B=1742-1760.
DR   PDB; 2YR3; NMR; -; A=510-601.
DR   PDB; 5JQA; X-ray; 1.80 A; B=1742-1761.
DR   PDB; 5JTH; X-ray; 1.84 A; B=1742-1761.
DR   PDB; 6C6M; X-ray; 2.50 A; A/B/C=405-507.
DR   PDBsum; 2CQV; -.
DR   PDBsum; 2K0F; -.
DR   PDBsum; 2YR3; -.
DR   PDBsum; 5JQA; -.
DR   PDBsum; 5JTH; -.
DR   PDBsum; 6C6M; -.
DR   AlphaFoldDB; Q15746; -.
DR   SMR; Q15746; -.
DR   BioGRID; 110722; 28.
DR   CORUM; Q15746; -.
DR   IntAct; Q15746; 87.
DR   MINT; Q15746; -.
DR   STRING; 9606.ENSP00000353452; -.
DR   BindingDB; Q15746; -.
DR   ChEMBL; CHEMBL2428; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q15746; -.
DR   GuidetoPHARMACOLOGY; 1552; -.
DR   iPTMnet; Q15746; -.
DR   MetOSite; Q15746; -.
DR   PhosphoSitePlus; Q15746; -.
DR   BioMuta; MYLK; -.
DR   DMDM; 300669714; -.
DR   EPD; Q15746; -.
DR   jPOST; Q15746; -.
DR   MassIVE; Q15746; -.
DR   MaxQB; Q15746; -.
DR   PaxDb; Q15746; -.
DR   PeptideAtlas; Q15746; -.
DR   PRIDE; Q15746; -.
DR   ProteomicsDB; 5180; -.
DR   ProteomicsDB; 60733; -. [Q15746-1]
DR   ProteomicsDB; 60734; -. [Q15746-2]
DR   ProteomicsDB; 60735; -. [Q15746-3]
DR   ProteomicsDB; 60736; -. [Q15746-4]
DR   ProteomicsDB; 60737; -. [Q15746-5]
DR   ProteomicsDB; 60738; -. [Q15746-6]
DR   ProteomicsDB; 60739; -. [Q15746-7]
DR   ProteomicsDB; 60740; -. [Q15746-8]
DR   Antibodypedia; 4044; 392 antibodies from 36 providers.
DR   DNASU; 4638; -.
DR   Ensembl; ENST00000346322.10; ENSP00000320622.6; ENSG00000065534.20. [Q15746-4]
DR   Ensembl; ENST00000360304.8; ENSP00000353452.3; ENSG00000065534.20. [Q15746-1]
DR   Ensembl; ENST00000360772.7; ENSP00000354004.3; ENSG00000065534.20. [Q15746-3]
DR   Ensembl; ENST00000418370.6; ENSP00000428967.1; ENSG00000065534.20. [Q15746-8]
DR   Ensembl; ENST00000508240.2; ENSP00000422984.2; ENSG00000065534.20. [Q15746-9]
DR   Ensembl; ENST00000583087.6; ENSP00000462118.1; ENSG00000065534.20. [Q15746-8]
DR   Ensembl; ENST00000685021.1; ENSP00000508447.1; ENSG00000065534.20. [Q15746-7]
DR   Ensembl; ENST00000685744.1; ENSP00000510047.1; ENSG00000065534.20. [Q15746-10]
DR   Ensembl; ENST00000686406.1; ENSP00000509044.1; ENSG00000065534.20. [Q15746-6]
DR   Ensembl; ENST00000686761.1; ENSP00000508758.1; ENSG00000065534.20. [Q15746-1]
DR   Ensembl; ENST00000687375.1; ENSP00000509867.1; ENSG00000065534.20. [Q15746-10]
DR   Ensembl; ENST00000688024.1; ENSP00000509803.1; ENSG00000065534.20. [Q15746-11]
DR   Ensembl; ENST00000693689.1; ENSP00000510503.1; ENSG00000065534.20. [Q15746-2]
DR   GeneID; 4638; -.
DR   KEGG; hsa:4638; -.
DR   MANE-Select; ENST00000360304.8; ENSP00000353452.3; NM_053025.4; NP_444253.3.
DR   UCSC; uc003egl.4; human. [Q15746-1]
DR   CTD; 4638; -.
DR   DisGeNET; 4638; -.
DR   GeneCards; MYLK; -.
DR   GeneReviews; MYLK; -.
DR   HGNC; HGNC:7590; MYLK.
DR   HPA; ENSG00000065534; Tissue enhanced (seminal vesicle, smooth muscle).
DR   MalaCards; MYLK; -.
DR   MIM; 249210; phenotype.
DR   MIM; 600922; gene.
DR   MIM; 613780; phenotype.
DR   neXtProt; NX_Q15746; -.
DR   OpenTargets; ENSG00000065534; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 2241; Megacystis-microcolon-intestinal hypoperistalsis syndrome.
DR   PharmGKB; PA31388; -.
DR   VEuPathDB; HostDB:ENSG00000065534; -.
DR   eggNOG; KOG0613; Eukaryota.
DR   GeneTree; ENSGT00940000157879; -.
DR   HOGENOM; CLU_000288_76_2_1; -.
DR   InParanoid; Q15746; -.
DR   OMA; MQVLEIQ; -.
DR   OrthoDB; 330091at2759; -.
DR   PhylomeDB; Q15746; -.
DR   TreeFam; TF314166; -.
DR   BRENDA; 2.7.11.18; 2681.
DR   PathwayCommons; Q15746; -.
DR   Reactome; R-HSA-445355; Smooth Muscle Contraction.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   SABIO-RK; Q15746; -.
DR   SignaLink; Q15746; -.
DR   SIGNOR; Q15746; -.
DR   BioGRID-ORCS; 4638; 9 hits in 1077 CRISPR screens.
DR   ChiTaRS; MYLK; human.
DR   EvolutionaryTrace; Q15746; -.
DR   GeneWiki; MYLK; -.
DR   GenomeRNAi; 4638; -.
DR   Pharos; Q15746; Tchem.
DR   PRO; PR:Q15746; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q15746; protein.
DR   Bgee; ENSG00000065534; Expressed in cauda epididymis and 210 other tissues.
DR   ExpressionAtlas; Q15746; baseline and differential.
DR   Genevisible; Q15746; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0001725; C:stress fiber; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004687; F:myosin light chain kinase activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0060414; P:aorta smooth muscle tissue morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0032060; P:bleb assembly; IMP:UniProtKB.
DR   GO; GO:0071476; P:cellular hypotonic response; IDA:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0090303; P:positive regulation of wound healing; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0006939; P:smooth muscle contraction; ISS:UniProtKB.
DR   GO; GO:0014820; P:tonic smooth muscle contraction; ISS:UniProtKB.
DR   CDD; cd00063; FN3; 1.
DR   CDD; cd14191; STKc_MLCK1; 1.
DR   Gene3D; 2.60.40.10; -; 10.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR015725; MLCK1_kinase_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00041; fn3; 1.
DR   Pfam; PF07679; I-set; 9.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00060; FN3; 1.
DR   SMART; SM00409; IG; 9.
DR   SMART; SM00408; IGc2; 9.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 9.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 1.
DR   PROSITE; PS50835; IG_LIKE; 9.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative promoter usage;
KW   Alternative splicing; Aortic aneurysm; ATP-binding; Calcium;
KW   Calmodulin-binding; Cell projection; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease variant; Disulfide bond;
KW   Immunoglobulin domain; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..1914
FT                   /note="Myosin light chain kinase, smooth muscle"
FT                   /id="PRO_0000024354"
FT   CHAIN           1..1910
FT                   /note="Myosin light chain kinase, smooth muscle,
FT                   deglutamylated form"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000403731"
FT   DOMAIN          33..122
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          161..249
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          414..503
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          514..599
FT                   /note="Ig-like C2-type 4"
FT   DOMAIN          620..711
FT                   /note="Ig-like C2-type 5"
FT   DOMAIN          721..821
FT                   /note="Ig-like C2-type 6"
FT   REPEAT          868..895
FT                   /note="1-1"
FT   REPEAT          896..923
FT                   /note="1-2"
FT   REPEAT          924..951
FT                   /note="1-3"
FT   REPEAT          952..979
FT                   /note="1-4"
FT   REPEAT          980..998
FT                   /note="1-5; truncated"
FT   REPEAT          999..1003
FT                   /note="2-1; truncated"
FT   REPEAT          1004..1015
FT                   /note="2-2"
FT   REPEAT          1016..1027
FT                   /note="2-3"
FT   REPEAT          1028..1039
FT                   /note="2-4"
FT   REPEAT          1040..1051
FT                   /note="2-5"
FT   REPEAT          1052..1063
FT                   /note="2-6"
FT   DOMAIN          1098..1186
FT                   /note="Ig-like C2-type 7"
FT   DOMAIN          1238..1326
FT                   /note="Ig-like C2-type 8"
FT   DOMAIN          1334..1426
FT                   /note="Fibronectin type-III"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1464..1719
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          1809..1898
FT                   /note="Ig-like C2-type 9"
FT   REGION          286..393
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          868..998
FT                   /note="5 X 28 AA approximate tandem repeats"
FT   REGION          923..963
FT                   /note="Actin-binding (calcium/calmodulin-sensitive)"
FT                   /evidence="ECO:0000250"
FT   REGION          932..1098
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          948..963
FT                   /note="Calmodulin-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          999..1063
FT                   /note="6 X 12 AA approximate tandem repeats"
FT   REGION          1061..1460
FT                   /note="Actin-binding (calcium/calmodulin-insensitive)"
FT                   /evidence="ECO:0000250"
FT   REGION          1192..1237
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1413..1446
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1711..1774
FT                   /note="Calmodulin-binding"
FT   REGION          1767..1787
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        292..319
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        327..350
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        935..949
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        995..1022
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1058..1088
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1767..1783
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1585
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         1470..1478
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1493
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         231
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         343
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         365
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         464
FT                   /note="Phosphotyrosine; by ABL1 and SRC"
FT                   /evidence="ECO:0000269|PubMed:11113114,
FT                   ECO:0000269|PubMed:12408982, ECO:0000269|PubMed:20861316"
FT   MOD_RES         471
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000269|PubMed:11113114,
FT                   ECO:0000269|PubMed:12408982"
FT   MOD_RES         556
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         608
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:19826488"
FT   MOD_RES         611
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         792
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         846
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         947
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         1438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1449
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         1575
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         1635
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:20861316"
FT   MOD_RES         1759
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         1760
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         1772
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1773
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         1776
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1778
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6PDN3"
FT   MOD_RES         1779
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   DISULFID        182..233
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        435..487
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        535..583
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        742..805
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        1119..1170
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        1830..1882
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         1..1760
FT                   /note="Missing (in isoform 6 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:10536370,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_018846"
FT   VAR_SEQ         1..1200
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_053791"
FT   VAR_SEQ         1..922
FT                   /note="Missing (in isoform 5 and isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:8575746, ECO:0000303|Ref.8"
FT                   /id="VSP_018845"
FT   VAR_SEQ         437..506
FT                   /note="VSGIPKPEVAWFLEGTPVRRQEGSIEVYEDAGSHYLCLLKARTRDSGTYSCT
FT                   ASNAQGQLSCSWTLQVER -> G (in isoform 2 and isoform 3B)"
FT                   /evidence="ECO:0000303|PubMed:10198165,
FT                   ECO:0000303|PubMed:15507455"
FT                   /id="VSP_004791"
FT   VAR_SEQ         1473..1545
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10198165"
FT                   /id="VSP_004793"
FT   VAR_SEQ         1655..1705
FT                   /note="Missing (in isoform 3A and isoform 3B)"
FT                   /evidence="ECO:0000303|PubMed:10198165"
FT                   /id="VSP_004794"
FT   VAR_SEQ         1790
FT                   /note="Missing (in isoform Del-1790, isoform 8 and isoform
FT                   9)"
FT                   /evidence="ECO:0000303|PubMed:10536370,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8575746"
FT                   /id="VSP_004795"
FT   VARIANT         21
FT                   /note="P -> H (in dbSNP:rs28497577)"
FT                   /id="VAR_057106"
FT   VARIANT         128
FT                   /note="A -> V (in dbSNP:rs143896146)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065570"
FT   VARIANT         133
FT                   /note="Q -> H (in dbSNP:rs140148380)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065571"
FT   VARIANT         160
FT                   /note="P -> R (in dbSNP:rs111256888)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065572"
FT   VARIANT         261
FT                   /note="V -> A (in dbSNP:rs3796164)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040847"
FT   VARIANT         276
FT                   /note="T -> A (in dbSNP:rs55846245)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040848"
FT   VARIANT         336
FT                   /note="P -> L (in dbSNP:rs35912339)"
FT                   /id="VAR_057107"
FT   VARIANT         378
FT                   /note="R -> H (in dbSNP:rs56378658)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040849"
FT   VARIANT         405
FT                   /note="M -> V (in dbSNP:rs35436690)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040850"
FT   VARIANT         443
FT                   /note="P -> S (in dbSNP:rs35156360)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040851"
FT   VARIANT         607
FT                   /note="R -> G"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040852"
FT   VARIANT         652
FT                   /note="P -> A (in dbSNP:rs750686734)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040853"
FT   VARIANT         656
FT                   /note="W -> C (in dbSNP:rs138172035)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21055718"
FT                   /id="VAR_040854"
FT   VARIANT         692
FT                   /note="T -> M (in dbSNP:rs776858093)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040855"
FT   VARIANT         701
FT                   /note="A -> T (in dbSNP:rs142835596)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040856"
FT   VARIANT         709
FT                   /note="V -> M (in dbSNP:rs112537316)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040857"
FT   VARIANT         845
FT                   /note="R -> C (in dbSNP:rs3732485)"
FT                   /id="VAR_057108"
FT   VARIANT         861
FT                   /note="L -> P (in dbSNP:rs3732486)"
FT                   /id="VAR_019986"
FT   VARIANT         877
FT                   /note="V -> M (in dbSNP:rs34542174)"
FT                   /id="VAR_057109"
FT   VARIANT         914
FT                   /note="D -> E (in dbSNP:rs3732487)"
FT                   /id="VAR_019987"
FT   VARIANT         1085
FT                   /note="T -> A (in dbSNP:rs75370906)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065573"
FT   VARIANT         1213
FT                   /note="V -> M (in AAT7; unknown pathological significance;
FT                   dbSNP:rs368390254)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065574"
FT   VARIANT         1399
FT                   /note="E -> K (in dbSNP:rs181663420)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065575"
FT   VARIANT         1458..1914
FT                   /note="Missing (in AAT7; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28401540"
FT                   /id="VAR_083423"
FT   VARIANT         1487..1914
FT                   /note="Missing (in AAT7; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28401540"
FT                   /id="VAR_083424"
FT   VARIANT         1491
FT                   /note="A -> S (in AAT7; decreases kinase activity;
FT                   dbSNP:rs1576422965)"
FT                   /evidence="ECO:0000269|PubMed:29544503"
FT                   /id="VAR_083425"
FT   VARIANT         1527
FT                   /note="A -> V (in dbSNP:rs34982967)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040858"
FT   VARIANT         1588
FT                   /note="P -> L (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; dbSNP:rs1576401641)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040859"
FT   VARIANT         1754
FT                   /note="A -> T (in AAT7; 4-fold reduced affinity for
FT                   calmodulin; decreased kinase activity compared to wild-type
FT                   protein)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065576"
FT   VARIANT         1759
FT                   /note="S -> P (in AAT7; 7-fold reduced affinity for
FT                   calmodulin; 6-fold decreased Vmax; dbSNP:rs387906781)"
FT                   /evidence="ECO:0000269|PubMed:21055718"
FT                   /id="VAR_065577"
FT   MUTAGEN         608
FT                   /note="K->A: Loss of acetylation and no kinase activity
FT                   repression by NAA10/ARD1."
FT                   /evidence="ECO:0000269|PubMed:19826488"
FT   CONFLICT        147
FT                   /note="P -> S (in Ref. 2; AAC18423, 3; AAD15922/AAD15923,
FT                   6; AAR29062, 7; AAQ02673 and 11; EAW79438/EAW79440)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        466
FT                   /note="D -> N (in Ref. 6; AAR29062)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        496
FT                   /note="L -> V (in Ref. 2; AAC18423, 3; AAD15922, 6;
FT                   AAR29062 and 7; AAQ02673)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        681
FT                   /note="C -> W (in Ref. 2; AAC18423 and 3;
FT                   AAD15921/AAD15922/AAD15923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        933
FT                   /note="V -> M (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        963
FT                   /note="S -> P (in Ref. 3; AAD15922)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1022
FT                   /note="P -> A (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1048..1050
FT                   /note="KPM -> EAH (in Ref. 1; CAA59685 and 8; BAB21504)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1162
FT                   /note="P -> L (in Ref. 3; AAD15922/AAD15923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1210
FT                   /note="L -> P (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1280
FT                   /note="E -> D (in Ref. 3; AAD15922/AAD15923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1284
FT                   /note="M -> I (in Ref. 3; AAD15922/AAD15923/AAD15924)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1300
FT                   /note="A -> G (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1316
FT                   /note="L -> S (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1326
FT                   /note="T -> S (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1478
FT                   /note="V -> C (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1511
FT                   /note="S -> T (in Ref. 3; AAD15922/AAD15923)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1518
FT                   /note="H -> P (in Ref. 6; AAR29061/AAR29062)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1563
FT                   /note="I -> T (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1609
FT                   /note="A -> P (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1634
FT                   /note="N -> I (in Ref. 6; AAR29061/AAR29062)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1639..1640
FT                   /note="GY -> D (in Ref. 3; AAD15922/AAD15923/AAD15924)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1639
FT                   /note="G -> R (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1648
FT                   /note="G -> R (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1658..1659
FT                   /note="LS -> PF (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1676
FT                   /note="A -> P (in Ref. 6; AAR29061/AAR29062)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1710..1711
FT                   /note="CT -> LA (in Ref. 1; CAA59685)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1897
FT                   /note="L -> H (in Ref. 3; AAD15922/AAD15923/AAD15924)"
FT                   /evidence="ECO:0000305"
FT   STRAND          415..418
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          423..425
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          431..438
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          444..449
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          458..466
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          469..476
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   HELIX           479..481
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          483..491
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          494..504
FT                   /evidence="ECO:0007829|PDB:6C6M"
FT   STRAND          512..518
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          523..526
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          531..534
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          536..541
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          546..553
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          560..562
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          565..570
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          581..586
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          591..595
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          598..601
FT                   /evidence="ECO:0007829|PDB:2YR3"
FT   STRAND          1239..1241
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1246..1250
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1255..1266
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1268..1277
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1281..1288
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1290..1297
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   TURN            1302..1304
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1306..1313
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1318..1320
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   STRAND          1323..1328
FT                   /evidence="ECO:0007829|PDB:2CQV"
FT   HELIX           1743..1760
FT                   /evidence="ECO:0007829|PDB:5JQA"
FT   INIT_MET        Q15746-8:1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         Q15746-8:2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   INIT_MET        Q15746-10:1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         Q15746-10:2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
SQ   SEQUENCE   1914 AA;  210715 MW;  2D094E161CE2D4BA CRC64;
     MGDVKLVASS HISKTSLSVD PSRVDSMPLT EAPAFILPPR NLCIKEGATA KFEGRVRGYP
     EPQVTWHRNG QPITSGGRFL LDCGIRGTFS LVIHAVHEED RGKYTCEATN GSGARQVTVE
     LTVEGSFAKQ LGQPVVSKTL GDRFSAPAVE TRPSIWGECP PKFATKLGRV VVKEGQMGRF
     SCKITGRPQP QVTWLKGNVP LQPSARVSVS EKNGMQVLEI HGVNQDDVGV YTCLVVNGSG
     KASMSAELSI QGLDSANRSF VRETKATNSD VRKEVTNVIS KESKLDSLEA AAKSKNCSSP
     QRGGSPPWAA NSQPQPPRES KLESCKDSPR TAPQTPVLQK TSSSITLQAA RVQPEPRAPG
     LGVLSPSGEE RKRPAPPRPA TFPTRQPGLG SQDVVSKAAN RRIPMEGQRD SAFPKFESKP
     QSQEVKENQT VKFRCEVSGI PKPEVAWFLE GTPVRRQEGS IEVYEDAGSH YLCLLKARTR
     DSGTYSCTAS NAQGQLSCSW TLQVERLAVM EVAPSFSSVL KDCAVIEGQD FVLQCSVRGT
     PVPRITWLLN GQPIQYARST CEAGVAELHI QDALPEDHGT YTCLAENALG QVSCSAWVTV
     HEKKSSRKSE YLLPVAPSKP TAPIFLQGLS DLKVMDGSQV TMTVQVSGNP PPEVIWLHNG
     NEIQESEDFH FEQRGTQHSL CIQEVFPEDT GTYTCEAWNS AGEVRTQAVL TVQEPHDGTQ
     PWFISKPRSV TASLGQSVLI SCAIAGDPFP TVHWLRDGKA LCKDTGHFEV LQNEDVFTLV
     LKKVQPWHAG QYEILLKNRV GECSCQVSLM LQNSSARALP RGREPASCED LCGGGVGADG
     GGSDRYGSLR PGWPARGQGW LEEEDGEDVR GVLKRRVETR QHTEEAIRQQ EVEQLDFRDL
     LGKKVSTKTL SEDDLKEIPA EQMDFRANLQ RQVKPKTVSE EERKVHSPQQ VDFRSVLAKK
     GTSKTPVPEK VPPPKPATPD FRSVLGGKKK LPAENGSSSA ETLNAKAVES SKPLSNAQPS
     GPLKPVGNAK PAETLKPMGN AKPAETLKPM GNAKPDENLK SASKEELKKD VKNDVNCKRG
     HAGTTDNEKR SESQGTAPAF KQKLQDVHVA EGKKLLLQCQ VSSDPPATII WTLNGKTLKT
     TKFIILSQEG SLCSVSIEKA LPEDRGLYKC VAKNDAGQAE CSCQVTVDDA PASENTKAPE
     MKSRRPKSSL PPVLGTESDA TVKKKPAPKT PPKAAMPPQI IQFPEDQKVR AGESVELFGK
     VTGTQPITCT WMKFRKQIQE SEHMKVENSE NGSKLTILAA RQEHCGCYTL LVENKLGSRQ
     AQVNLTVVDK PDPPAGTPCA SDIRSSSLTL SWYGSSYDGG SAVQSYSIEI WDSANKTWKE
     LATCRSTSFN VQDLLPDHEY KFRVRAINVY GTSEPSQESE LTTVGEKPEE PKDEVEVSDD
     DEKEPEVDYR TVTINTEQKV SDFYDIEERL GSGKFGQVFR LVEKKTRKVW AGKFFKAYSA
     KEKENIRQEI SIMNCLHHPK LVQCVDAFEE KANIVMVLEI VSGGELFERI IDEDFELTER
     ECIKYMRQIS EGVEYIHKQG IVHLDLKPEN IMCVNKTGTR IKLIDFGLAR RLENAGSLKV
     LFGTPEFVAP EVINYEPIGY ATDMWSIGVI CYILVSGLSP FMGDNDNETL ANVTSATWDF
     DDEAFDEISD DAKDFISNLL KKDMKNRLDC TQCLQHPWLM KDTKNMEAKK LSKDRMKKYM
     ARRKWQKTGN AVRAIGRLSS MAMISGLSGR KSSTGSPTSP LNAEKLESEE DVSQAFLEAV
     AEEKPHVKPY FSKTIRDLEV VEGSAARFDC KIEGYPDPEV VWFKDDQSIR ESRHFQIDYD
     EDGNCSLIIS DVCGDDDAKY TCKAVNSLGE ATCTAELIVE TMEEGEGEGE EEEE
//
